

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claim 1 (original): A method for inducing hemostasis in a subject, comprising administering to said subject an inducer of P-selectin activity, such that hemostasis occurs.

Claim 2 (original): The method of claim 1, wherein the inducer of P-selectin activity increases the level of soluble P-selectin polypeptide in the plasma of the subject.

Claim 3 (original): The method of claim 2, wherein the inducer of P-selectin activity increases the proteolytic cleavage of P-selectin from a cell surface.

Claim 4 (original): The method of claim 2, wherein the inducer of P-selectin activity increases P-selectin gene expression.

Claim 5 (original): The method of claim 1, wherein the inducer of P-selectin activity binds to a P-selectin receptor or ligand and mimics the activity of a P-selectin polypeptide.

Claim 6 (original): The method of claim 5, wherein the inducer of P-selectin activity is an antibody to a P-selectin receptor or ligand.

Claim 7 (original): The method of claim 5, wherein the P-selectin ligand is PSGL-1.

Claim 8 (original): The method of claim 6, wherein the antibody is an antibody to PSGL-1.

Claim 9 (original): A method for inducing hemostasis in a subject, comprising administering to said subject a soluble P-selectin polypeptide, such that hemostasis occurs.

Claim 10 (original): A method for inducing hemostasis in a subject, comprising administering to said subject an isolated nucleic acid molecule comprising a nucleotide sequence which encodes a soluble P-selectin polypeptide, such that hemostasis occurs.

Claim 11 (original): A method for inducing hemostasis in a subject, comprising administering to said subject a recombinant cell expressing soluble P-selectin polypeptide, such that hemostasis occurs.

Claim 12 (original): A method for treating or preventing a disorder associated with hypocoagulation in a subject, comprising administering to said subject an inducer of Pselectin activity, such that the disorder associated with hypocoagulation is treated or prevented.

Claim 13 (original): The method of claim 12, wherein said disorder is a hemorrhagic disorder.

Claim 14 (original): The method of claim 12, wherein said disorder is hemophilia.

Claim 15 (original): The method of claim 12, wherein the inducer of P-selectin activity increases the level of soluble P-selectin polypeptide in the plasma of the subject.

Claim 16 (original): A method for treating or preventing a disorder associated with hypocoagulation in a subject, comprising administering to said subject a soluble Pselectin polypeptide.

Claim 17 (original): A method for treating a vasculature-associated disease in a subject, comprising administering to said subject an inducer of P-selectin activity, such that the vasculature-associated disease is treated.

Claim 18 (original): The method of claim 17, wherein said vasculature-associated disease is a tumor.

Claim 19 (original): The method of claim 18, wherein said subject is further treated with a molecule effective to induce a procoagulant state in tumor associated vasculature.

Claim 20 (original): The method of claim 19, wherein said molecule comprises a first binding region that binds to a component of a tumor cell or tumor associated vasculature, operatively linked to a coagulation factor or a second binding region that binds to a coagulation factor.

Claim 21 (original): The method of claim 20, wherein said first binding region comprises an antibody, or an antigen binding fragment thereof, that binds to VCAM-1, operatively linked to tissue factor.

Claim 22 (original): The method of claim 17, wherein the inducer of P-selectin activity increases the level of soluble P-selectin polypeptide in the plasma of the subject.

Claims 23-49 (canceled)

Claim 50 (new): The method of claims 12 or 14, wherein the inducer of P-selectin activity is selected from the group consisting of small molecules, peptides, peptidomimetics, and antibodies.

Claim 51 (new): The method of claims 12 or 14, wherein the inducer of P-selectin activity is a fusion protein.

Claim 52 (new): The method of claim 51, wherein the fusion protein comprises a soluble P-selectin polypeptide operatively linked to an immunoglobulin.

Claim 52 (new): The method of claim 52, wherein the immunoglobulin is a human IgG1, and the Fc region of the immunoglobulin is fused to the C-terminus of at least one soluble P-selectin polypeptide. sequence.

Claim 53 (new): A pharmaceutical composition for administration to a subject *in vivo*, said pharmaceutical composition comprising a fusion protein.

Claim 54 (new): The pharmaceutical composition of claim 53 wherein the fusion protein comprises a soluble P-selectin polypeptide operatively linked to an immunoglobulin.

Claim 55 (new): The pharmaceutical composition of claim 54 wherein the immunoglobulin is a human IgG1, and the Fc region of the immunoglobulin is fused to the C-terminus of at least one soluble P-selectin polypeptide.

Claim 56 (new): A pharmaceutical composition for administration to a subject *in vivo*, said pharmaceutical composition comprising a small molecule.